{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T21:10:55Z","timestamp":1773436255314,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T00:00:00Z","timestamp":1483920000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00405-016-4431-5","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T04:54:08Z","timestamp":1483937648000},"page":"1891-1896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT)"],"prefix":"10.1007","volume":"274","author":[{"given":"Kornelia E. C.","family":"Wirsching","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Haubner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"K\u00fchnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,9]]},"reference":[{"issue":"3","key":"4431_CR1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ajmg.1320320302","volume":"32","author":"H Plauchu","year":"1989","unstructured":"Plauchu H, de Chadar\u00e9vian JP, Bideau A, Robert JM (1989) Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 32(3):291\u2013297","journal-title":"Am J Med Genet"},{"issue":"1","key":"4431_CR2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1017\/S0022215100136370","volume":"111","author":"PA Lennox","year":"1997","unstructured":"Lennox PA, Harries M, Lund VJ, Howard DJ (1997) A retrospective study of the role of the argon laser in the management of epistaxis secondary to hereditary haemorrhagic telangiectasia. J Laryngol Otol 111(1):34\u201337","journal-title":"J Laryngol Otol"},{"issue":"6","key":"4431_CR3","first-page":"407","volume":"14","author":"BJ Folz","year":"2004","unstructured":"Folz BJ, Lippert BM, Wollstein AC, Tennie J, Happle R, Werner JA (2004) Mucocutaneous telangiectases of the head and neck in individuals with hereditary hemorrhagic telangiectasia\u2014analysis of distribution and symptoms. Eur J Dermatol 14(6):407\u2013411","journal-title":"Eur J Dermatol"},{"issue":"9","key":"4431_CR4","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1288\/00005537-199409000-00023","volume":"104","author":"JL Gluckman","year":"1994","unstructured":"Gluckman JL, Portugal LG (1994) Modified Young\u2019s procedure for refractory epistaxis due to hereditary hemorrhagic telangiectasia. Laryngoscope 104(9):1174\u20131177","journal-title":"Laryngoscope"},{"issue":"5","key":"4431_CR5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1017\/S0022215100067426","volume":"81","author":"A Young","year":"1967","unstructured":"Young A (1967) Closure of the nostrils in atrophic rhinitis. J Laryngol Otol 81(5):515\u2013524","journal-title":"J Laryngol Otol"},{"issue":"4","key":"4431_CR6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","volume":"120","author":"JB Hoag","year":"2010","unstructured":"Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA (2010) An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 120(4):838\u2013843","journal-title":"Laryngoscope"},{"key":"4431_CR7","doi-asserted-by":"publisher","DOI":"10.21053\/ceo.2016.00318","author":"KEC Wirsching","year":"2016","unstructured":"Wirsching KEC, K\u00fchnel TS (2016) Update on clinical strategies in hereditary hemorrhagic telangiectasia from an ENT point of view. Clin Exp Otorhinolaryngol. doi: 10.21053\/ceo.2016.00318","journal-title":"Clin Exp Otorhinolaryngol"},{"issue":"5","key":"4431_CR8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1177\/194589240501900515","volume":"19","author":"TS K\u00fchnel","year":"2005","unstructured":"K\u00fchnel TS, Wagner BH, Schurr CP, Strutz J (2005) Clinical strategy in hereditary hemorrhagic telangiectasia. Am J Rhinol 19(5):508\u2013513","journal-title":"Am J Rhinol"},{"issue":"2","key":"4431_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jmg.2009.069013","volume":"48","author":"ME Faughnan","year":"2011","unstructured":"Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J et al (2011) International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48(2):73\u201387. doi: 10.1136\/jmg.2009.069013","journal-title":"J Med Genet"},{"issue":"11","key":"4431_CR10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-2006-933691","volume":"131","author":"D Slotosch","year":"2006","unstructured":"Slotosch D, Koller M, Werner JA, Folz BJ (2006) Recurrent nosebleeds in patients with hereditary hemorrhagic telangiectasia. Dtsch Med Wochenschr 131(11):535\u2013539","journal-title":"Dtsch Med Wochenschr"},{"issue":"4","key":"4431_CR11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/lary.23736","volume":"123","author":"DD Reh","year":"2013","unstructured":"Reh DD, Hur K, Merlo CA (2013) Efficacy of a topical sesame\/rose geranium oil compound in patients with hereditary hemorrhagic telangiectasia associated epistaxis. Laryngoscope 123(4):820\u2013822","journal-title":"Laryngoscope"},{"issue":"12 Pt 1","key":"4431_CR12","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1288\/00005537-198412000-00003","volume":"94","author":"SM Shapshay","year":"1984","unstructured":"Shapshay SM, Oliver P (1984) Treatment of hereditary hemorrhagic telangiectasia by Nd-YAG laser photocoagulation. Laryngoscope 94(12 Pt 1):1554\u20131556","journal-title":"Laryngoscope"},{"issue":"6","key":"4431_CR13","first-page":"384","volume":"26","author":"GA Velegrakis","year":"1997","unstructured":"Velegrakis GA, Prokopakis EP, Papadakis CE, Helidonis ES (1997) Nd:YAG laser treatment of recurrent epistaxis in heredity hemorrhagic telangiectasia. J Otolaryngol 26(6):384\u2013386","journal-title":"J Otolaryngol"},{"issue":"8","key":"4431_CR14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1055\/s-2007-997467","volume":"76","author":"JA Werner","year":"1997","unstructured":"Werner JA, Lippert BM, Geisthoff UW, Rudert H (1997) Nd:YAG laser therapy of recurrent epistaxis in hereditary hemorrhagic telangiectasia. Laryngorhinootologie 76(8):495\u2013501","journal-title":"Laryngorhinootologie"},{"issue":"4","key":"4431_CR15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archderm.1973.01620190047011","volume":"107","author":"HC Kwaan","year":"1973","unstructured":"Kwaan HC, Silverman S (1973) Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol 107(4):571\u2013573","journal-title":"Arch Dermatol"},{"issue":"5","key":"4431_CR16","first-page":"1031","volume":"98","author":"CL Shovlin","year":"2007","unstructured":"Shovlin CL, Laila Sulaiman N, Govani FS, Jackson JE, Begbie ME (2007) Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost 98(5):1031\u20131039","journal-title":"Thromb Haemost"},{"issue":"2","key":"4431_CR17","first-page":"69","volume":"89","author":"BA Flanagan","year":"2012","unstructured":"Flanagan BA, Collins C, Parra S (2012) Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options. Cutis 89(2):69\u201372","journal-title":"Cutis"},{"issue":"9","key":"4431_CR18","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/jth.12654","volume":"12","author":"S Gaillard","year":"2014","unstructured":"Gaillard S, Dupuis-Girod S, Boutitie F, Riviere S, Moriniere S, Hatron PY, Manfredi G et al (2014) Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost 12(9):1494\u20131502. doi: 10.1111\/jth.12654","journal-title":"J Thromb Haemost"},{"issue":"2","key":"4431_CR19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s001060100537","volume":"50","author":"UW Geisthoff","year":"2002","unstructured":"Geisthoff UW, Schneider G, Fischinger J, Plinkert PK (2002) Heredit\u00e4re h\u00e4morrhagische Teleangiektasie (Morbus Osler). Eine interdisziplin\u00e4re Herausforderung. HNO 50(2):114\u2013128","journal-title":"HNO"},{"issue":"6","key":"4431_CR20","first-page":"818","volume":"90","author":"H Sadick","year":"2005","unstructured":"Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, Lux A (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90(6):818\u2013828","journal-title":"Haematologica"},{"issue":"2","key":"4431_CR21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1024\/0301-1526\/a000253","volume":"42","author":"A Chavan","year":"2013","unstructured":"Chavan A, Schumann-Binarsch S, Luthe L, Nickau B, Elsasser A, Kuhnel T, Geisthoff U et al (2013) Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). VASA 42(2):106\u2013110","journal-title":"VASA"},{"issue":"9","key":"4431_CR22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00277-006-0147-8","volume":"85","author":"D Flieger","year":"2006","unstructured":"Flieger D, Hainke S, Fischbach W (2006) Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 85(9):631\u2013632","journal-title":"Ann Hematol"},{"issue":"9","key":"4431_CR23","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","volume":"307","author":"S Dupuis-Girod","year":"2012","unstructured":"Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A et al (2012) Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307(9):948\u2013955","journal-title":"JAMA"},{"issue":"5","key":"4431_CR24","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/lary.20159","volume":"119","author":"J Simonds","year":"2009","unstructured":"Simonds J, Miller F, Mandel J, Davidson TM (2009) The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 119(5):988\u2013992","journal-title":"Laryngoscope"},{"issue":"3","key":"4431_CR25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/lary.21415","volume":"121","author":"TT Karnezis","year":"2011","unstructured":"Karnezis TT, Davidson TM (2011) Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 121(3):636\u2013638","journal-title":"Laryngoscope"},{"issue":"2","key":"4431_CR26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00405-011-1721-9","volume":"269","author":"C Rohrmeier","year":"2012","unstructured":"Rohrmeier C, Sachs HG, Kuehnel TS (2012) A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 269(2):531\u2013536. doi: 10.1007\/s00405-011-1721-9","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"6","key":"4431_CR27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/hed.23655","volume":"37","author":"D Riss","year":"2015","unstructured":"Riss D, Burian M, Wolf A, Kranebitter V, Kaider A, Arnoldner C (2015) Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Head Neck 37(6):783\u2013787","journal-title":"Head Neck"},{"issue":"1","key":"4431_CR28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1017\/S0022215100136369","volume":"111","author":"VJ Lund","year":"1997","unstructured":"Lund VJ, Howard DJ (1997) Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia. J Laryngol Otol 111(1):30\u201333","journal-title":"J Laryngol Otol"},{"issue":"5","key":"4431_CR29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2500\/ajra.2012.26.3809","volume":"26","author":"SL Richer","year":"2012","unstructured":"Richer SL, Geisthoff UW, Livada N, Ward PD, Johnson L, Mainka A, Henderson KJ et al (2012) The Young\u2019s procedure for severe epistaxis from hereditary hemorrhagic telangiectasia. Am J Rhinol Allergy 26(5):401\u2013404","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"4431_CR30","doi-asserted-by":"publisher","first-page":"H959","DOI":"10.1152\/ajpheart.01251.2009","volume":"299","author":"JM Lopez-Novoa","year":"2010","unstructured":"Lopez-Novoa JM, Bernabeu C (2010) The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 299(4):H959\u2013H974. doi: 10.1152\/ajpheart.01251.2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"4431_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.amjoto.2010.06.003","volume":"32","author":"L Bruschini","year":"2011","unstructured":"Bruschini L, Seccia V, Dallan I (2011) A silicone nasal swab for the treatment of severe and recalcitrant epistaxis in hereditary hemorrhagic telangiectasia: an alternative to surgical nostril closure. Am J Otolaryngol 32(4):301\u2013303. doi: 10.1016\/j.amjoto.2010.06.003","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"4431_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00405-014-3086-3","volume":"272","author":"B Al Kadah","year":"2015","unstructured":"Al Kadah B, Papaspyrou G, Schneider M, Schick B (2015) First experiences with an individual nasal olive in patients with hereditary haemorrhagic telangiectasia (HHT). Eur Arch Otorhinolaryngol 272(1):117\u2013122. doi: 10.1007\/s00405-014-3086-3","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"4431_CR33","first-page":"40","volume":"43","author":"BJ Folz","year":"2005","unstructured":"Folz BJ, Tennie J, Lippert BM, Werner JA (2005) Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease. Rhinology 43(1):40\u201346","journal-title":"Rhinology"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-016-4431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00405-016-4431-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-016-4431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T03:38:58Z","timestamp":1749872338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00405-016-4431-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,9]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["4431"],"URL":"https:\/\/doi.org\/10.1007\/s00405-016-4431-5","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,9]]}}}